COMPANY

ProKidney

12 open jobs · last seen Oct 26, 2026 · 10 sources

Keywords: cell therapy renal chronic kidney disease kidney failure Diabetic Kidney Disease Chronic Kidney Diseases Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus Congenital Anomalies of Kidney and Urinary Tract Type 2 Diabetes Renal Autologous Cell Therapy Renal Autologous Cell Therapy (REACT/ rilparencel) Neo-Kidney Augment

Profile checked Oct 10, 2026

12Open jobs 10Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Quality Assurance Specialist 2, Batch Release Contractor	Winston-Salem, North Carolina, United States	Oct 21, 2026	Oct 22, 2026
Quality Assurance Specialist 1, Batch Release Contractor	Winston-Salem, North Carolina, United States	Oct 21, 2026	Oct 22, 2026
Manufacturing Cell Processing Specialist 1 Contractor	Winston-Salem, North Carolina, United States	Oct 13, 2026	Oct 21, 2026
Associate Director, IT GxP & Quality Systems	Winston-Salem, North Carolina, United States	Sep 29, 2026	Oct 21, 2026
Material Handler 1 Contractor	Winston-Salem, North Carolina, United States	Sep 28, 2026	Oct 21, 2026

See all 12 jobs

Timeline

Jul 17, 2024 Trial start Phase 3: A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease source ↗
Dec 11, 2023 Trial start —: A Long-Term Follow-Up Study of Participants Exposed to REACT source ↗
Nov 23, 2023 Trial start —: Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product source ↗
Jul 11, 2023 Trial start Phase 1: A Study of Participants With Chronic Kidney Disease Previously Treated With REACT source ↗
Jan 5, 2022 Trial start Phase 3: Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease source ↗
Jul 27, 2021 Trial start Phase 2: Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007) source ↗
Aug 13, 2019 Trial start Phase 1: A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). source ↗
Apr 25, 2018 Trial start Phase 2: A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease source ↗
2016-09 Trial start Phase 2: A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease source ↗
2016-07 Trial start Phase 2: Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) source ↗

Upcoming milestones

2028-01 (ESTIMATED) · · A Long-Term Follow-Up Study of Participants Exposed to REACT · NCT05918523
2029-12 (ESTIMATED) · Phase 3 · Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease · NCT05099770
May 31, 2030 (ESTIMATED) · · Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product · NCT06790498

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT06790498	Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product	Not listed	Enrolling by invitation	Nov 23, 2023	May 31, 2030 (estimated)
NCT05918523	A Long-Term Follow-Up Study of Participants Exposed to REACT	Not listed	Recruiting	Dec 11, 2023	2028-01 (estimated)
NCT05099770	Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease	Phase 3	Active, not recruiting	Jan 5, 2022	2029-12 (estimated)
NCT05018416	Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)	Phase 2	Completed	Jul 27, 2021	May 20, 2025 (actual)
NCT02836574	A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease	Phase 2	Completed	2016-09	2023-12 (actual)
NCT03270956	A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease	Phase 2	Completed	Apr 25, 2018	Nov 17, 2022 (actual)
NCT05694169	A Study of Participants With Chronic Kidney Disease Previously Treated With REACT	Phase 1	Terminated	Jul 11, 2023	Mar 19, 2024 (actual)
NCT05286853	A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease	Phase 3	Withdrawn	Jul 17, 2024	Sep 3, 2024 (actual)
NCT04115345	A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).	Phase 1	Completed	Aug 13, 2019	Jan 31, 2023 (actual)
NCT02525263	Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)	Phase 2	Terminated	2016-07	2017-05 (actual)

Open jobs 12

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Quality Assurance Specialist 2, Batch Release Contractor	Winston-Salem, North Carolina, United States	Oct 21, 2026	Oct 22, 2026	Not stated
Quality Assurance Specialist 1, Batch Release Contractor	Winston-Salem, North Carolina, United States	Oct 21, 2026	Oct 22, 2026	Not stated
Manufacturing Cell Processing Specialist 1 Contractor	Winston-Salem, North Carolina, United States	Oct 13, 2026	Oct 21, 2026	Not stated
Associate Director, IT GxP & Quality Systems	Winston-Salem, North Carolina, United States	Sep 29, 2026	Oct 21, 2026	Not stated
Material Handler 1 Contractor	Winston-Salem, North Carolina, United States	Sep 28, 2026	Oct 21, 2026	Not stated
Director of Sterility Assurance	Winston-Salem, North Carolina, United States	Sep 28, 2026	Oct 21, 2026	Not stated
Associate Director, Raw Materials MSAT	Winston-Salem, North Carolina, United States	Sep 28, 2026	Oct 21, 2026	Not stated
Director, CMC Project Management	Remote; Winston-Salem, North Carolina, United States	Sep 10, 2026	Oct 21, 2026	Not stated
Quality Assurance Specialist 2, Floor Support	Winston-Salem, North Carolina, United States	Sep 4, 2026	Oct 21, 2026	Not stated
Senior Manager, Validation	Winston-Salem, North Carolina, United States	Sep 1, 2026	Oct 21, 2026	Not stated
Sr. Director, Biostatistics	Remote	Aug 19, 2026	Oct 21, 2026	Not stated
Sr. Director, Quality Operations	Winston-Salem, North Carolina, United States	Feb 2, 2026	Oct 21, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.